Patents by Inventor Sean D. Monahan

Sean D. Monahan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10660970
    Abstract: Described herein are block copolymers, and methods of making and utilizing such copolymers. The described block copolymers are disruptive of a cellular membrane, including an extracellular membrane, an intracellular membrane, a vesicle, an organelle, an endosome, a liposome, or a red blood cell. Preferably, in certain instances, the block copolymer disrupts the membrane and enters the intracellular environment. In specific examples, the block copolymer is endosomolytic and capable of delivering an oligonucleotide (e.g., an mRNA) to a cell. Compositions comprising a block copolymer and an oligonucleotide (e.g., an mRNA) are also disclosed.
    Type: Grant
    Filed: August 16, 2019
    Date of Patent: May 26, 2020
    Assignee: Genevant Sciences GmbH
    Inventors: Sean D. Monahan, Michael S. DeClue, Pierrot Harvie, Russell N. Johnson, Amber E. Paschal, Mary G. Prieve, Debashish Roy, Charbel Diab, Michael E. Houston, Jr., Anna Galperin, Maher Qabar
  • Patent number: 10646582
    Abstract: Described herein are block copolymers, and methods of making and utilizing such copolymers. The described block copolymers are disruptive of a cellular membrane, including an extracellular membrane, an intracellular membrane, a vesicle, an organelle, an endosome, a liposome, or a red blood cell. Preferably, in certain instances, the block copolymer disrupts the membrane and enters the intracellular environment. In specific examples, the block copolymer is endosomolytic and capable of delivering an oligonucleotide (e.g., an mRNA) to a cell. Compositions comprising a block copolymer and an oligonucleotide (e.g., an mRNA) are also disclosed.
    Type: Grant
    Filed: November 30, 2017
    Date of Patent: May 12, 2020
    Assignee: Genevant Sciences GmbH
    Inventors: Sean D. Monahan, Michael S. DeClue, Pierrot Harvie, Russell N. Johnson, Amber E. Paschal, Mary G. Prieve, Debashish Roy, Charbel Diab, Michael E. Houston, Jr., Anna Galperin, Maher Qabar
  • Publication number: 20200078313
    Abstract: Disclosed are branched PEG molecules, including branched PEG-lipids and branched-PEG proteins, as well as related compositions and methods for making branched PEG molecules. Also disclosed are related compositions, systems, and methods for in vivo delivery of therapeutic and diagnostic agents.
    Type: Application
    Filed: December 29, 2017
    Publication date: March 12, 2020
    Applicant: Genevant Sciences GmbH.
    Inventors: Debashish ROY, Jean-Rene E. ELLA-MENYE, Sean D. MONAHAN, Pierrot HARVIE, Anna GALPERIN, Michael E. HOUSTON, JR., Mary G. PRIEVE
  • Publication number: 20190388551
    Abstract: Described herein are block copolymers, and methods of making and utilizing such copolymers. The described block copolymers are disruptive of a cellular membrane, including an extracellular membrane, an intracellular membrane, a vesicle, an organelle, an endosome, a liposome, or a red blood cell. Preferably, in certain instances, the block copolymer disrupts the membrane and enters the intracellular environment. In specific examples, the block copolymer is endosomolytic and capable of delivering an oligonucleotide (e.g., an mRNA) to a cell. Compositions comprising a block copolymer and an oligonucleotide (e.g., an mRNA) are also disclosed.
    Type: Application
    Filed: August 16, 2019
    Publication date: December 26, 2019
    Applicant: GENEVANT SCIENCES GMBH
    Inventors: Sean D. MONAHAN, Michael S. DeCLUE, Pierrot HARVIE, Russell N. JOHNSON, Amber E. PASCHAL, Mary G. PRIEVE, Debashish ROY, Charbel DIAB, Michael E. HOUSTON, Anna GALPERIN, Maher QABAR
  • Publication number: 20180243433
    Abstract: Described herein are block copolymers, and methods of making and utilizing such copolymers. The described block copolymers are disruptive of a cellular membrane, including an extracellular membrane, an intracellular membrane, a vesicle, an organelle, an endosome, a liposome, or a red blood cell. Preferably, in certain instances, the block copolymer disrupts the membrane and enters the intracellular environment. In specific examples, the block copolymer is endosomolytic and capable of delivering an oligonucleotide (e.g., an mRNA) to a cell. Compositions comprising a block copolymer and an oligonucleotide (e.g., an mRNA) are also disclosed.
    Type: Application
    Filed: November 30, 2017
    Publication date: August 30, 2018
    Inventors: Sean D. Monahan, Michael S. DeClue, Pierrot Harvie, Russell N. Johnson, Amber E. Paschal, Mary G. Prieve, Debashish Roy, Charbel Diab, Michael E. Houston, JR., Anna Galperin, Maher Qabar
  • Publication number: 20180221402
    Abstract: Disclosed are methods for delivering a therapeutic or diagnostic agent to the cytosol of a cell in a subject. The disclosed methods generally include administering to the subject an effective amount of a lipid nanoparticle comprising the therapeutic or diagnostic agent and an effective amount of a membrane-destabilizing polymer. Also disclosed are related compositions and delivery systems.
    Type: Application
    Filed: January 21, 2016
    Publication date: August 9, 2018
    Inventors: Mary G. PRIEVE, Michael E. HOUSTON, JR., Pierrot HARVIE, Sean D. MONAHAN
  • Patent number: 9867885
    Abstract: Described herein are block copolymers, and methods of making and utilizing such copolymers. The described block copolymers are disruptive of a cellular membrane, including an extracellular membrane, an intracellular membrane, a vesicle, an organelle, an endosome, a liposome, or a red blood cell. Preferably, in certain instances, the block copolymer disrupts the membrane and enters the intracellular environment. In specific examples, the block copolymer is endosomolytic and capable of delivering an oligonucleotide (e.g., an mRNA) to a cell. Compositions comprising a block copolymer and an oligonucleotide (e.g., an mRNA) are also disclosed.
    Type: Grant
    Filed: July 30, 2014
    Date of Patent: January 16, 2018
    Assignee: PhaseRx, Inc.
    Inventors: Sean D Monahan, Michael S Declue, Pierrot Harvie, Russell N Johnson, Amber E Paschal, Mary G Prieve, Debashish Roy, Charbel Diab, Michael E Houston, Jr., Anna Galperin, Maher Qabar
  • Publication number: 20170049801
    Abstract: Provided herein are multiblock copolymers, as well as micelles and therapeutic compositions thereof.
    Type: Application
    Filed: September 1, 2016
    Publication date: February 23, 2017
    Applicants: University of Washington, PhaseRx, Inc.
    Inventors: Mary G. Prieve, Paul H. Johnson, Patrick S. Stayton, Allan S. Hoffman, Robert W. Overell, Anna S. Gall, Amber E.E. Paschal, Charbel Diab, Priyadarsi De, Michael S. DeClue, Sean D. Monahan
  • Patent number: 9464300
    Abstract: Provided herein are multiblock copolymers, as well as micelles and therapeutic compositions thereof.
    Type: Grant
    Filed: November 6, 2009
    Date of Patent: October 11, 2016
    Assignees: University of Washington, PhaseRx, Inc.
    Inventors: Mary G. Prieve, Paul H. Johnson, Patrick S. Stayton, Allan S. Hoffman, Robert W. Overell, Anna S. Gall, Amber E. E. Paschal, Charbel Diab, Priyadarsi De, Michael S. DeClue, Sean D. Monahan
  • Patent number: 9415113
    Abstract: Provided herein are monomers incorporating folate or other targeting agent, polymers prepared therefrom, polymers prepared therefrom having a therapeutic agent covalently coupled thereto, as well as micelles and therapeutic compositions thereof.
    Type: Grant
    Filed: November 17, 2010
    Date of Patent: August 16, 2016
    Assignees: University of Washington, PhaseRx, Inc.
    Inventors: Sean D. Monahan, Paul H. Johnson, Michael S. DeClue, Priyadarsi De, Anna S. Gall, Patrick S. Stayton, Allan S. Hoffman, Charbel Diab
  • Publication number: 20160206750
    Abstract: Described herein are block copolymers, and methods of making and utilizing such copolymers. The described block copolymers are disruptive of a cellular membrane, including an extracellular membrane, an intracellular membrane, a vesicle, an organelle, an endosome, a liposome, or a red blood cell. Preferably, in certain instances, the block copolymer disrupts the membrane and enters the intracellular environment. In specific examples, the block copolymer is endosomolytic and capable of delivering an oligonucleotide (e.g., an mRNA) to a cell. Compositions comprising a block copolymer and an oligonucleotide (e.g., an mRNA) are also disclosed.
    Type: Application
    Filed: July 30, 2014
    Publication date: July 21, 2016
    Inventors: Sean D MONAHAN, Michael S DECLUE, Pierrot HARVIE, Russell N JOHNSON, Amber E PASCHAL, Mary G PRIEVE, Debashish ROY, Charbel DIAB, Michael E HOUSTON, Jr., Anna GALPERIN, Maher QABAR
  • Publication number: 20130017167
    Abstract: Provided herein are polymers having a therapeutic agent covalently coupled to a hydrophobic block thereof, as well as micelles and therapeutic compositions thereof.
    Type: Application
    Filed: November 12, 2010
    Publication date: January 17, 2013
    Applicant: University of Washington through its Center for Commercialization
    Inventors: Sean D. Monahan, Paul H. Johnson, Charbel Diab, Priyadarsi De, Patrick S. Stayton, Allan S. Hoffman
  • Publication number: 20130011362
    Abstract: Provided herein are monomers incorporating folate or other targeting agent, polymers prepared therefrom, polymers prepared therefrom having a therapeutic agent covalently coupled thereto, as well as micelles and therapeutic compositions thereof.
    Type: Application
    Filed: November 17, 2010
    Publication date: January 10, 2013
    Applicants: PhaseRx, Inc., University of Washington through its Center for Commercialization
    Inventors: Sean D. Monahan, Paul H. Johnson, Michael S. DeClue, Priyadarsi De, Anna S. Gall, Patrick S. Stayton, Allan S. Hoffman, Charbel Diab
  • Patent number: 8137695
    Abstract: The present invention is directed to compounds, compositions, and methods useful for delivering polynucleotides or other cell-impermeable molecules to mammalian cells. Described are polyconjugates systems that incorporate targeting, anti-opsonization, anti-aggregation, and transfection activities into small biocompatible in vivo delivery vehicles. The use of multiple reversible linkages connecting component parts provides for physiologically responsive activity modulation.
    Type: Grant
    Filed: August 17, 2007
    Date of Patent: March 20, 2012
    Assignee: Arrowhead Madison Inc.
    Inventors: David B. Rozema, James E. Hagstrom, Jason Klein, David L. Lewis, Sean D. Monahan, Darren H. Wakefield, Jon A. Wolff, So Wong
  • Publication number: 20110286957
    Abstract: Provided herein are multiblock copolymers, as well as micelles and therapeutic compositions thereof.
    Type: Application
    Filed: November 6, 2009
    Publication date: November 24, 2011
    Applicants: PHASERX, INC., UNIVERSITY OF WASHINGTON
    Inventors: Mary G. Prieve, Paul H. Johnson, Patrick S. Stayton, Allan S. Hoffman, Robert W. Overell, Anna S. Gall, Amber E.E. Paschal, Charbel Diab, Priyadarsi De, Michael S. DeClue, Sean D. Monahan
  • Patent number: 8017109
    Abstract: The present invention is directed to membrane active polymers useful for cellular delivery of compounds. Described are polyconjugates systems that incorporate targeting, anti-opsonization, anti-aggregation, and transfection activities into small biocompatible in vivo delivery conjugates. The use of reversible modification provides for physiologically responsive activity modulation.
    Type: Grant
    Filed: June 17, 2008
    Date of Patent: September 13, 2011
    Assignee: Roche Madison Inc.
    Inventors: Darren H. Wakefield, David B. Rozema, Sean D. Monahan, Lori Higgs, Jon A. Wolff, James E. Hagstrom
  • Patent number: 8008355
    Abstract: The present invention is directed to membrane active polymers useful for cellular delivery of compounds. Described are polyconjugates systems that incorporate targeting, anti-opsonization, anti-aggregation, and transfection activities into small biocompatible in vivo delivery conjugates. The use of reversible modification provides for physiologically responsive activity modulation.
    Type: Grant
    Filed: June 17, 2008
    Date of Patent: August 30, 2011
    Assignee: Roche Madison Inc.
    Inventors: David B. Rozema, Darren H. Wakefield, Sean D. Monahan, Lori Higgs, Jon A. Wolff, James E. Hagstrom
  • Patent number: 7985406
    Abstract: The present invention is directed to a class of membrane active polymers useful for cellular delivery of compounds. Conjugation of the described membrane active polymers to targeting, anti-opsonization, and anti-aggregation agents provides polymers suitable for in vivo delivery. The use of multiple reversible linkages connecting component parts provides for physiologically responsive activity modulation.
    Type: Grant
    Filed: May 19, 2008
    Date of Patent: July 26, 2011
    Assignee: Roche Madison Inc.
    Inventors: Sean D. Monahan, Darren H. Wakefield, David B. Rozema, Lori Higgs, Jon A. Wolff, James E. Hagstrom
  • Patent number: 7601367
    Abstract: Described is a deliverable composition with low toxicity comprising an amphipathic compound, a polycation, and a siRNA. The composition may be used in the process of delivering a siRNA to an animal cell or more particularly, a mammal cell.
    Type: Grant
    Filed: May 14, 2004
    Date of Patent: October 13, 2009
    Assignee: Mirus Bio LLC
    Inventors: Sean D. Monahan, David L. Lewis, Hans Herweijer, Jon A. Wolff, James E. Hagstrom, Aaron G. Loomis, Vladimir Trubetskoy, Lori Higgs
  • Patent number: 7589059
    Abstract: Disclosed is a system for providing in vivo delivery of molecules or complexes to extravascular mammalian cells using an intravascular administration route. The molecules or complexes are inserted in an injection solution into a mammalian vasculature. Insertion of the injection solution at an appropriate rate transiently increases the volume of extravascular fluid in the tissue thereby facilitating delivery of the molecule to the cell.
    Type: Grant
    Filed: July 28, 2003
    Date of Patent: September 15, 2009
    Assignee: Roche Madison Inc.
    Inventors: Jon A. Wolff, Vladimir G. Budker, Hans Herweijer, James E. Hagstrom, Sean D. Monahan, Julia Hegge, Vladimir Subbotin